Recent evidence suggests that hypoglycemia may play an important role in the vascular complications of diabetes ([@B1]). Hypoglycemia causes oxidative stress ([@B2]), inflammation ([@B3]), and endothelial dysfunction ([@B4]). Oxidative stress is considered the key player in the pathogenesis of diabetes complications ([@B5]). During hyperglycemia, oxidative stress is produced at the mitochondrial level ([@B5]), similarly as in hypoglycemia ([@B2]). Therefore, oxidative stress might be considered the common factor linking hyperglycemia, hypoglycemia, and the vascular complications of diabetes. Consistent with this hypothesis is the evidence that hyperglycemia ([@B6]) and hypoglycemia both produce endothelial dysfunction and inflammation through the generation of oxidative stress ([@B4],[@B7]). Endothelial dysfunction and inflammation are well-recognized pathogenic factors for vascular disease, particularly in diabetes ([@B8]).

There is, however, evidence that free radical production rises, not only during hypoglycemia but particularly during glucose reperfusion after hypoglycemia ([@B9]). In both mice and cultured neurons, hypoglycemia, followed by different concentrations of glucose reperfusion, has been linked to a degree of superoxide production and neuronal death that increased proportionally with glucose concentrations during the reperfusion period ([@B9]).

Until now, little attention has been given to studying the effects of recovery from hypoglycemia. The aim of this study was to evaluate these effects and, in particular, to determine if the level of glycemia reached during recovery could have a different impact, in vivo, on oxidative stress generation, inflammation, and endothelial function.

RESEARCH DESIGN AND METHODS {#s1}
===========================

**Subjects**. {#s2}
-------------

Twenty healthy subjects and 22 matched individuals with type 1 diabetes were studied ([Table 1](#T1){ref-type="table"}). Results of bedside tests of autonomic function in individuals with type 1 diabetes were within normal reference ranges ([@B10]), and they did not exhibit hypoglycemia unawareness, as based on the methods of Gold et al. ([@B11]). Type 1 diabetic individuals had no major macro- or microcomplications of diabetes. The study excluded individuals with type 1 diabetes who had had at least one major episode of hypoglycemia in the preceding 2 years. Type 1 diabetic individuals were treated with multiple daily insulin injections. All subjects were nonsmokers and had a normal blood count, plasma lipids, plasma electrolytes, liver and renal function, and blood pressure. No subject was taking medications known to affect neuroendocrine responses to hypoglycemia or inflammation. Studies were approved by the ethical committees of the respective research institutions involved, and all participants gave written informed consent.

###### 

Baseline characteristics of control subjects and of type 1 diabetic patients

![](2993tbl1)

All subjects were admitted to the Research Center on the evening before each experiment and ate a meal. Individuals with type 1 diabetes received a continuous low-dose infusion of insulin to normalize plasma glucose. The insulin infusion was adjusted overnight to maintain blood glucose between 4.4 and 7.2 mmol/L.

Hypoglycemia experiments. {#s3}
-------------------------

Three different experiments, each following a 2-h period of induced hypoglycemia and lasting for 2 hours, were planned for each subject in a randomized order: reaching and maintaining normoglycemia, reaching and maintaining hyperglycemia, or reaching and maintaining hyperglycemia with simultaneous infusion of vitamin C. Each subject underwent the experiments at intervals of 2 weeks or longer.

All subjects fasted overnight for 10 h. In all experiments, an initial period of 120 min was allowed to elapse, followed by a 120-min hyperinsulinemic hypoglycemic experimental period. At time 120 min, a primed constant (9.0 pmol · kg^−1^ · min^−1^) infusion of insulin (Actrapid, Novo Nordisk, Copenhagen, Denmark) began and continued for 240 min. The rate of glucose decrease was controlled (*∼*0.08 mmol/min), and glucose nadir (2.9 mmol/L), a level that likely elicits minimal counterregulatory effect, was achieved using a modification of the glucose clamp technique. During the clamp period, plasma glucose was measured every 5 min, and a 20% dextrose infusion was adjusted so that plasma glucose levels were held constant at 2.9 ± 0.1 mmol/L ([@B12]). Potassium chloride (20 mmol/L) was infused during the clamp to reduce insulin-induced hypokalemia.

After this period of induced hypoglycemia, common to all the experiments, recovery from hypoglycemia was achieved for 120 min, in random order, by reaching and maintaining normoglycemia (4.5 mmol/L), by reaching and maintaining hyperglycemia (15 mmol/L), or by reaching and maintaining hyperglycemia with the simultaneous infusion of vitamin C (30 mg/min) ([@B13]). Therefore, glycemia was normalized for the next 360 min.

At baseline (120 min from the start of the experiment) and after 2, 4, and 10 h, blood samples were taken for biochemical assays of glycemia, and plasma levels of nitrotyrosine and 8-iso prostaglandin F2α (8-iso-PGF2α), both markers of oxidative stress, as well as intracellular adhesion molecule-1a (ICAM-1a) and interleukin-6 (IL-6), markers of inflammation. Endothelial function was measured by flow-mediated dilatation (FMD).

Biochemical and clinical measurements. {#s4}
--------------------------------------

Cholesterol, triglycerides, HDL and LDL cholesterol, and plasma nitrotyrosine were measured as previously described ([@B14]). Plasma glucose was measured by the glucose-oxidase method, HbA~1c~ by high-performance liquid chromatography, and insulin by microparticle enzyme immunoassay (Abbott Laboratories, Wiesbaden, Germany). Plasma 8-iso-PGF2α (Cayman Chemical, Ann Arbor, MI), soluble (s)ICAM-1 (British Biotechnology, Abington, Oxon, U.K.), and IL-6 (R&D Systems, Minneapolis, MN) were determined using commercially available kits.

Endothelial function was evaluated measuring the FMD of the brachial artery ([@B15]). At the end of each test, sublingual nitroglycerin (0.3 mg) was administered and 3-min endothelium-independent vasodilatation measured.

Statistical analysis. {#s5}
---------------------

Sample size was selected according to previous studies ([@B3]). Data are expressed as means ± SE. The Kolmogorov-Smirnov algorithm was used to determine whether each variable had a normal distribution. Comparisons of baseline data among the groups were performed using the unpaired Student *t* test or Mann-Whitney *U* test, where indicated. The changes in variables during the tests were assessed by two-way ANOVA with repeated measures or Kolmogorov-Smirnov test, where indicated. If differences reached statistical significance, post hoc analyses with the two-tailed paired *t* test or Wilcoxon signed rank test for paired comparisons were used to assess differences at individual time periods in the study. Statistical significance was defined as *P* \< 0.05.

RESULTS {#s6}
=======

Basal FMD was significantly decreased in people with type 1 diabetes compared with control subjects, whereas 8-iso-PGF2α, nitrotyrosine, sICAM-1, and IL-6 were significantly increased ([Table 1](#T1){ref-type="table"}). Similarly to previous studies ([@B3],[@B4]), FMD significantly decreased after 2 h of hypoglycemia, whereas sICAM-1, 8-iso-PGF2α, nitrotyrosine, and IL-6 significantly increased compared with basal values in control subjects and in subjects with type 1 diabetes ([Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

![Levels for glucose, sICAM-1, FMD, nitrotyrosine, IL-6, and 8-iso-PGF2α in type 1 diabetes are shown for hypoglycemia + hyperglycemia (solid line), hypoglycemia + normoglycemia (dashed line), and hypoglycemia + hyperglycemia + vitamin C (dashed-dotted line). \**P* \< 0.05 vs. basal. \#*P* \< 0.01 vs. basal. §*P* \< 0.01 vs. hypoglycemia + normoglycemia. "*P* \< 0.05 vs. hypoglycemia + normoglycemia. *P* \< 0.01 vs. hypoglycemia + hyperglycemia + vitamin C.](2993fig1){#F1}

![Levels for glucose, sICAM-1, FMD, nitrotyrosine, IL-6, and 8-iso-PGF2α in normal healthy control subjects are shown for hypoglycemia + hyperglycemia (solid line), hypoglycemia + normoglycemia (dashed line), and hypoglycemia + hyperglycemia + vitamin C (dashed-dotted line). \**P* \< 0.05 vs. basal. \#*P* \< 0.01 vs. basal. §*P* \< 0.01 vs. hypoglycemia + normoglycemia. *P* \< 0.01 vs. hypoglycemia + hyperglycemia + vitamin C.](2993fig2){#F2}

Recovery from hypoglycemia had a dramatically different effect when obtained reaching normoglycemia or hyperglycemia.

After 2 h of recovery in normoglycemia, FMD was still significantly decreased in control subjects and in people with type 1 diabetes, whereas sICAM-1, 8-iso-PGF2α, nitrotyrosine, and IL-6 were still significantly increased compared with basal values, reaching the baseline values after 6 h of normal glycemia ([Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

After 2 h of recovery in hyperglycemia, FMD was even more significantly decreased compared with basal, than recovery in normoglycemia, in both control subjects and people with type 1 diabetes ([Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). The decrease was more pronounced in control subjects than in participants with diabetes (41 vs. 16%). Levels of sICAM-1, 8-iso-PGF2α, nitrotyrosine, and IL-6 were significantly increased in a consistent manner, in both control subjects and people with type 1 diabetes, compared with basal, than after recovery in normoglycemia ([Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

After 6 h of glucose normalization after recovery in hyperglycemia, FMD was still decreased compared with basal in normal control subjects and people with diabetes ([Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). Compared with basal, sICAM-1, 8-iso-PGF2α, and nitrotyrosine were significantly increased in a consistent manner in control subjects and people with type 1 diabetes ([Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

These phenomena were significantly attenuated in control subjects and in people with type 1 diabetes when recovery in hyperglycemia was accompanied by the simultaneous infusion of vitamin C: FMD decreased less, whereas sICAM-1, 8-iso-PGF2α, nitrotyrosine, and IL-6 were less increased ([Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). Endothelial-independent vasodilatation was not affected in any of the experiments.

DISCUSSION {#s7}
==========

This study confirms that hypoglycemia induces endothelial dysfunction, oxidative stress, and inflammation. However, it also shows that the way in which recovery from hypoglycemia takes place may also have an effect on cardiovascular risk. When recovery from hypoglycemia is obtained reaching normoglycemia, the deleterious effects of the previous hypoglycemia are mainly counterbalanced, whereas when recovery is obtained reaching hyperglycemia, endothelial function, oxidative stress, and inflammation are further worsened.

In recent years, hyperglycemia and hypoglycemia have both been confirmed as affecting atherothrombosis and inflammation ([@B1],[@B6]). However, the role of hypoglycemia in this setting has received particular attention. Two epidemiologic studies have determined that hypoglycemia results in an increased risk of cardiovascular disease and all-cause mortality ([@B16],[@B17]), whereas the increase in cardiovascular mortality in people with type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial ([@B18]) and possibly in the Veterans Affairs Diabetes Trial (VADT) ([@B19]) and Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) ([@B20]) studies has caused concern, because intensive treatment had tripled the frequency of severe hypoglycemia.

The situation remains unclear, however. In the ACCORD trial, epidemiologic analyses were perplexing; for example, earlier severe hypoglycemic episodes were a risk factor for death and occurred three times as often as in the intensive glycemic treatment group, but the excess of deaths in that group was not accounted for by those subjects who had suffered earlier episodes of severe hypoglycemia ([@B21]). In the ADVANCE trial, severe hypoglycemia was strongly associated with increased risks of a range of adverse clinical outcomes; however, although it is possible that severe hypoglycemia contributes to adverse outcomes, the data indicate that hypoglycemia is just as likely to be a marker of vulnerability to such events ([@B20]). None of these studies devoted attention to how patients recovered from hypoglycemia, and these kinds of data are probably not available. For the first time, our data raise the interesting hypothesis that the way in which recovery from hypoglycemia takes place may, on the one hand, have a role in determining the outcomes, and, on the other, in confusion regarding the interpretation of results.

The way by which recovery from hypoglycemia through hyperglycemia worsens the situation is, convincingly, an increase in oxidative stress. When hyperglycemia after hypoglycemia was accompanied by the simultaneous infusion of the antioxidant vitamin C, the expected improvement in oxidative stress was accompanied by a simultaneous improvement in endothelial function and inflammation. This finding is consistent with the evidence reported in cells and animals ([@B9]), suggesting that hyperglycemia after hypoglycemia produces a "reperfusion-like" effect ([@B22]).

In our opinion, it is interesting that recovery from hypoglycemia with normoglycemia in control subjects and in people with type 1 diabetes was not completely without negative effects. In both groups, even improved endothelial function, inflammation, and oxidative stress were not completely recovered, suggesting that hypoglycemia regardless might produce a sort of legacy effect, even for a short period. The concept of "legacy" or "metabolic memory" is well recognized in hyperglycemia and indicates the possibility of a long-lasting deleterious effect persisting for some time after glucose normalization ([@B23]). This concept is not new at all to hypoglycemia; for example, baroreflex sensitivity and sympathetic response to hypotension are attenuated after previous hypoglycemia ([@B24]). Interestingly, oxidative stress is the mediator of the hyperglycemia-induced metabolic memory ([@B23]). Moreover, the "memory" phenomenon, after heart ischemia--reperfusion, is also well known: alterations of metabolism in the heart may last for even days after a period of ischemia--reperfusion ([@B22]). It is possible that after hypoglycemia, alterations similar to those occurring in the reperfused heart are produced in endothelial cells. This is supported by the similarity of the pathways activated in the two situations, as reported in basic experiments ([@B25]).

In conclusion, our study shows for the first time that the way in which recovery from hypoglycemia takes place could have a dramatic impact on cardiovascular risk in diabetes, suggesting that in clinical practice, a gradual correction of blood glucose in patients with hypoglycemia may be preferred to a more rapid correction and hyperglycemia. This hypothesis, of course, needs to be confirmed in large-scale, specifically designed clinical trials. However, because hypoglycemia as a risk factor for cardiovascular disease has become increasingly evident ([@B1]) and because hypoglycemia is a frequent event in the life of people with diabetes, we believe that our study may already give a rationale for a more careful treatment of hypoglycemia in daily practice.
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